Alopecia Areata: Current Treatments and New Directions

Dahabreh, Dante; Jung, Seungyeon; Renert-Yuval, Yael; Bar, Jonathan; Del Duca, Ester; Guttman-Yassky, Emma

doi:10.1007/s40257-023-00808-1

Cited by 15 publications

(6 citation statements)

References 197 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The JAK-STAT signalling pathway is primarily involved in regulating cell proliferation, differentiation, stem cell maintenance, cytokine signalling, and regulation of the immune system [ 12 ]. Out of nine JAK inhibitors that have been approved by the FDA for the treatment of many diseases, baricitinib was approved for the treatment of hair loss in 2022 and ritlecitinib in 2023 [ 13 , 14 ]. Here, we present the discovery of MJ04 as a potent JAK-STAT signaling inhibitor involved in promoting hair regrowth in mice and humans.…”

Section: Introductionmentioning

confidence: 99%

Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter

Hossain,

Khalid,

Akhter

et al. 2024

J Transl Med

View full text Add to dashboard Cite

JAK-STAT signalling pathway inhibitors have emerged as promising therapeutic agents for the treatment of hair loss. Among different JAK isoforms, JAK3 has become an ideal target for drug discovery because it only regulates a narrow spectrum of γc cytokines. Here, we report the discovery of MJ04, a novel and highly selective 3-pyrimidinylazaindole based JAK3 inhibitor, as a potential hair growth promoter with an IC50 of 2.03 nM. During in vivo efficacy assays, topical application of MJ04 on DHT-challenged AGA and athymic nude mice resulted in early onset of hair regrowth. Furthermore, MJ04 significantly promoted the growth of human hair follicles under ex-vivo conditions. MJ04 exhibited a reasonably good pharmacokinetic profile and demonstrated a favourable safety profile under in vivo and in vitro conditions. Taken together, we report MJ04 as a highly potent and selective JAK3 inhibitor that exhibits overall properties suitable for topical drug development and advancement to human clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter

Hossain,

Khalid,

Akhter

et al. 2024

J Transl Med

View full text Add to dashboard Cite

show abstract

“…Since 2022, the FDA has approved two Janus Kinase (JAK) inhibitors for treating AA, baricitinib and ritlecitinib. However, both drugs are recent approvals and will require further analysis to assess for long-term effectiveness and side effects [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Lasers in the management of alopecia: a review of established therapies and advances in treatment

Jean-Pierre,

Pulumati,

Kasheri

et al. 2024

Lasers Med Sci

View full text Add to dashboard Cite

Alopecia, also known as hair loss, is a highly prevalent condition affecting millions of men and women in the United States and worldwide, making it one of the most common complaints by patients presenting to a dermatologist. The symptomology on the presentation of alopecia can be highly variable, ranging from diffuse thinning of hair, discrete and localized patches completely absent of hair, or noticing significant shedding when brushing and showering. Although alopecia does not have a direct negative health impact on patients, it is nonetheless a debilitating disease as it can profoundly impact an individual’s self-image and psychosocial well-being. There are multiple treatment options available to patients with alopecia, and they are typically tailored to the patient’s needs and preferences. The most common of these is the Food and Drug Administration-approved drugs for alopecia, minoxidil, and finasteride. However, both of these are known to be partially efficacious for all patients, so clinicians often use different modalities in conjunction with them, in particular laser-based therapies. This review article will provide a comprehensive assessment of lasers and other light therapies that may be used to manage the two most common types of alopecia: androgenetic alopecia and alopecia areata.

show abstract

“…It may potentially be a superior solution for the treatment of AA. 4 Therefore, we treated five patients with diverse backgrounds using a regimen of Upadacitinib extended-release tablets at a dosage of 15 mg orally once daily. The severity and treatment effect of each patient were assessed before and after treatment using the SALT (Severity of Alopecia Tool) method, 5 as recommended by the evaluation guidelines of the American Academy of Dermatology in the United States.…”

Section: Introductionmentioning

confidence: 99%

Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series

He,

Yang,

Lai

et al. 2024

CCID

View full text Add to dashboard Cite

Alopecia Areata is a hair disorder influenced by factors such as genetics, immune system, and environmental triggers. The pathogenesis of this condition is still unclear, leading to unsatisfactory current treatments and causing a large number of patients to suffer from it. Janus kinase inhibitors are a new class of drugs that have emerged in recent years and are expected to be promising therapeutic tools for alopecia areata. We report five patients with varying backgrounds and severity of alopecia areata. All of them had received conventional therapy without success. Five patients took Upadacitinib at a dose of 15 mg once daily, and all of them achieved satisfactory efficacy. No adverse events were observed during the treatment of 5 patients.

show abstract

Alopecia Areata: Current Treatments and New Directions

Cited by 15 publications

References 197 publications

Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter

Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter

Lasers in the management of alopecia: a review of established therapies and advances in treatment

Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series

Contact Info

Product

Resources

About